Japanese and US pharma majors Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have reported that Study 201, investigating Alzheimer’s candidate BAN2401, has not reached its primary endpoint after 12 months.
The efficacy of five dose groups of BAN2401 was evaluated at 12 months based on Eisai’s in-house developed novel endpoint Alzheimer’s disease Composite Score (ADCOMS). None of the groups reached the predefined efficacy endpoint.
The blinded study will continue, and the firms hope that a final analysis at 18 months will demonstrate clinically-significant results. Final data will arrive mid-2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze